Category: Cancer Treatments

Home / Cancer Treatments

Categories

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

May 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manu...

Tumor Infiltrating lymphocytes (TIL) Immunotherapy in India

April 2023: Using the body's immune system to fight cancer cells is the goal of the promising cancer treatment method known as tumour infiltrating lymphocytes (TIL) immunotherapy. The process entails...

Sam Neill, “Jurassic Park” actor, has been diagnosed with blood cancer

March 2023: The first chapter of Sam Neill's memoir would be a tremendous shock to someone who had no prior knowledge of it. It starts out funny enough: a great yarn about his daughter Elena being qu...

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has co...

A Study of CD19/BCMA CAR-T Cells Therapy for Patients With Refractory Sjogren’s Syndrome

Detailed Description: Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, there is a risk of d...

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" d...

Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma

Brief Summary: A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma   Detailed Description: This i...

Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States

23rd March 2023: The preclinical and early-stage cancer cell therapies being developed by Shanghai biotech Oricell have received an additional $45 million in funding, the company announced on Tuesday...

KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previousl...

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening d...

Scan the code